Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Table 7. High-Risk Disease (Stages IIIB, IVB)

Chemotherapy (No. of Cycles)a Radiation (Gy) Stage  No. of Patients Event-Free Survival (No. of Years of Follow-up) Survival (No. of Years of Follow-up) 
OEPA/OPPA (2) + COPP (4) [18]IFRT (20–35)IIEB, IIIEA/B, IIIB, IVA/B26591% (5)N/A
OEPA/OPPA (2) + COPDAC (4) [41]IFRT (20–35)IIEB, IIIEA/B, IIIB, IVA/B23986.9% (5)94.9% (5)
ABVE-PC (3-5) [35]IFRT (21)IB, IIA, IIIA16385% (5)95% (5)
BEACOPP (4); COPP/ABV (4) (RER; girls) [45]NoneIIB, IIIB, IV3894% (5)97% (5)
BEACOPP (4); ABVD (2) (RER; boys) [45]IFRT (21)IIB, IIIB, IV34
BEACOPP (8) (SER) [45]IFRT (21)IIB, IIIB, IV25

E = extralymphatic; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number; RER = rapid early response; SER = slow early response.
aRefer to Table 4 for more information about the chemotherapy regimens.

References

  1. Dörffel W, Lüders H, Rühl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215 (3): 139-45, 2003 May-Jun.  [PUBMED Abstract]

  2. Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009.  [PUBMED Abstract]

  3. Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010.  [PUBMED Abstract]

  4. Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011.  [PUBMED Abstract]